1. Lung function outcome at school age in very low birth weight children;Cazzato;Pediatr Pulmonol,2013
2. a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group;Palivizumab;Pediatrics,1998
3. Respiratory syncytial virus and premature infants born at 32 weeks’ gestation or earlier: hospitalization and economic implications of prophylaxis;Stevens;Arch Pediatr Adolesc Med,2000
4. Long-term burden and respiratory effects of respiratory syncytial virus hospitalization in preterm infants: the SPRING study;Carbonell-Estrany;PLoS One,2015
5. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease;Feltes;J Pediatr,2003